E
MiNK Therapeutics, Inc.
INKT
$8.41
-$0.34-3.89%
E
Sell
3/25/2025Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 3/25/2025 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.457 to -$1.2467, EBIT declined 131.74% from -$1.88M to -$4.37M, and the quick ratio declined from 0.86 to 0.66.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 3/25/2025 due to a major decline in the solvency index, growth index and volatility index. Earnings per share declined from -$0.457 to -$1.2467, EBIT declined 131.74% from -$1.88M to -$4.37M, and the quick ratio declined from 0.86 to 0.66.
D
Sell
3/13/2025Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 3/13/2025 due to an increase in the volatility index and total return index.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 3/13/2025 due to an increase in the volatility index and total return index.
E
Sell
2/21/2025Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 2/21/2025 due to a decline in the volatility index.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 2/21/2025 due to a decline in the volatility index.
D
Sell
2/4/2025Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 2/4/2025 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.7274 to -$0.457, and EBIT increased 35.05% from -$2.9M to -$1.88M.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 2/4/2025 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.7274 to -$0.457, and EBIT increased 35.05% from -$2.9M to -$1.88M.
E
Sell
10/5/2023Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 10/5/2023 due to a decline in the total return index and volatility index.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 10/5/2023 due to a decline in the total return index and volatility index.
D
Sell
9/20/2023Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 9/20/2023 due to an increase in the volatility index and valuation index.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 9/20/2023 due to an increase in the volatility index and valuation index.
E
Sell
8/30/2023Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index and total return index.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 8/30/2023 due to a decline in the volatility index and total return index.
D
Sell
8/15/2023Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 8/15/2023 due to an increase in the volatility index.
E
Sell
7/19/2023Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 7/19/2023 due to a decline in the volatility index.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 7/19/2023 due to a decline in the volatility index.
D
Sell
7/3/2023Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 7/3/2023 due to an increase in the total return index and volatility index.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 7/3/2023 due to an increase in the total return index and volatility index.
E
Sell
6/12/2023Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 6/12/2023 due to a decline in the volatility index.
D
Sell
5/25/2023Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 5/25/2023 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2298 to -$0.1674, EBIT increased 25.8% from -$7.89M to -$5.85M, and operating cash flow increased 1.45% from -$4.43M to -$4.37M.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 5/25/2023 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2298 to -$0.1674, EBIT increased 25.8% from -$7.89M to -$5.85M, and operating cash flow increased 1.45% from -$4.43M to -$4.37M.
E
Sell
5/15/2023Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 5/15/2023 due to a decline in the volatility index and growth index.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 5/15/2023 due to a decline in the volatility index and growth index.
D
Sell
4/26/2023Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 4/26/2023 due to an increase in the volatility index and total return index.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 4/26/2023 due to an increase in the volatility index and total return index.
E
Sell
4/11/2023Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 4/11/2023 due to a decline in the volatility index.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 4/11/2023 due to a decline in the volatility index.
D
Sell
3/27/2023Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 3/27/2023 due to an increase in the valuation index and total return index.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 3/27/2023 due to an increase in the valuation index and total return index.
E
Sell
3/14/2023Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 2/23/2023 due to an increase in the valuation index.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 2/23/2023 due to an increase in the valuation index.
E
Sell
2/8/2023Downgrade
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 1.71 to 1.31.
MiNK Therapeutics, Inc. (INKT) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 1.71 to 1.31.
D
Sell
11/4/2022Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 11/4/2022 due to an increase in the volatility index, solvency index and growth index. Earnings per share increased from -$0.2321 to -$0.1818.
MiNK Therapeutics, Inc. (INKT) was upgraded to D- from E+ on 11/4/2022 due to an increase in the volatility index, solvency index and growth index. Earnings per share increased from -$0.2321 to -$0.1818.
E
Sell
7/1/2022Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to E+ from E on 7/1/2022 due to an increase in the solvency index, efficiency index and valuation index.
MiNK Therapeutics, Inc. (INKT) was upgraded to E+ from E on 7/1/2022 due to an increase in the solvency index, efficiency index and valuation index.
E
Sell
4/1/2022Upgraded
MiNK Therapeutics, Inc. (INKT) was upgraded to E from E- on 4/1/2022 due to a significant increase in the solvency index. The quick ratio increased from 0.01 to 2.36.
MiNK Therapeutics, Inc. (INKT) was upgraded to E from E- on 4/1/2022 due to a significant increase in the solvency index. The quick ratio increased from 0.01 to 2.36.
E
Sell
1/10/2022None
MiNK Therapeutics, Inc. (INKT) was downgraded to E- from U on 01/10/2022.
MiNK Therapeutics, Inc. (INKT) was downgraded to E- from U on 01/10/2022.
NASDAQ
04/04/2025 4:00PM Eastern
Quotes delayed
